PDCD1 and non-small cell lung carcinoma: With the development of immune checkpoint inhibitors, including programmed cell death-ligand 1 (PD-L1) and programmed cell death protein-1 (PD-1) inhibitors, the systemic therapy of non-small cell lung cancer (NSCLC) has entered the era of immunotherapy.